Vascular disease and cognitive impairment

References

• Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J. Neurological Sci.226(1–2), 75–80 (2004).
   PubMed Web of Science ®Google Scholar
• Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol.4(11), 752–759 (2005).
   PubMed Web of Science ®Google Scholar
• Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke39(1), 36–41 (2008).
   PubMed Web of Science ®Google Scholar
• Fein G, Di Sclafani V, Tanabe J et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology55(11), 1626–1635 (2000).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. The pathology of ischemic-vascular dementia: an update. J. Neurol. Sci.203–204 153–157 (2002).
   Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet368(9533), 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA277(10), 813–817 (1997).
   PubMed Web of Science ®Google Scholar
• Wen Y, Yu WH, Maloney B et al. Transcriptional regulation of β-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron57(5), 680–690 (2008).
   PubMed Web of Science ®Google Scholar
• Wen Y, Yang SH, Liu R et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochimica Biophysica Acta1772(4), 473–483 (2007).
   PubMed Web of Science ®Google Scholar
• Smith CD, Snowdon DA, Wang H, Markesbery WR. White matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology54(4), 833–842 (2000).
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol.6(7), 611–619 (2007).
   PubMed Web of Science ®Google Scholar
• Frisoni GB, Galluzzi S, Pantoni L, Filippi M. The effect of white matter lesions on cognition in the elderly – small but detectable. Nat. Clin. Prac.3(11), 620–627 (2007).
   PubMedGoogle Scholar
• Wright CB, Festa JR, Paik MC et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke39(3), 800–805 (2008).
   PubMed Web of Science ®Google Scholar
• Libon DJ, Price CC, Giovannetti T et al. Linking MRI hyperintensities with patterns of neuropsychological impairment: evidence for a threshold effect. Stroke39(3), 806–813 (2008).
   PubMed Web of Science ®Google Scholar
• Delano-Wood L, Abeles N, Sacco JM, Wierenga CE, Horne NR, Bozoki A. Regional white matter pathology in mild cognitive impairment: differential influence of lesion type on neuropsychological functioning. Stroke39(3), 794–799 (2008).
   PubMed Web of Science ®Google Scholar
• Hachinski VC. The decline and resurgence of vascular dementia. CMAJ142(2), 107–111 (1990).
   PubMed Web of Science ®Google Scholar
• Roman GC. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA258(13), 1782–1788 (1987).
   PubMed Web of Science ®Google Scholar
• Swartz RH, Stuss DT, Gao F, Black SE. Independent cognitive effects of atrophy and diffuse subcortical and thalamico-cortical cerebrovascular disease in dementia. Stroke39(3), 822–830 (2008).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch. Neurol.64(4), 570–575 (2007).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol.154(7), 635–641 (2001).
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology53(9), 1937–1942 (1999).
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu–Asia Aging Study. Diabetes51(4), 1256–1262 (2002).
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging26(Suppl. 1), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Skoog I, Lernfelt B, Landahl S et al. 15-year longitudinal study of blood pressure and dementia. Lancet347(9009), 1141–1145 (1996).
   PubMed Web of Science ®Google Scholar
• Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke28(2), 316–321 (1997).
   PubMed Web of Science ®Google Scholar
• Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology69(10), 998–1005 (2007).
   PubMed Web of Science ®Google Scholar
• Reitz C, Luchsinger J, Tang MX, Mayeux R. Effect of smoking and time on cognitive function in the elderly without dementia. Neurology65(6), 870–875 (2005).
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology(2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology64(2), 277–281 (2005).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ322(7300), 1447–1451 (2001).
   PubMed Web of Science ®Google Scholar
• Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ312(7034), 805–808 (1996).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bennett DA et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology62(11), 2021–2024 (2004).
   PubMed Web of Science ®Google Scholar
• Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology65(6), 892–897 (2005).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA283(12), 1615–1617 (2000).
   PubMed Web of Science ®Google Scholar
• Reaven GM, Laws A. Insulin Resistance: The Metabolic Syndrome X. Humana Press, Totowa, New Jersey, USA (1999).
   Google Scholar
• Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA100(7), 4162–4167 (2003).
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease. Med. Hypotheses64(6), 1205–1207 (2005).
   PubMed Web of Science ®Google Scholar
• Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta. Neuropathol. (Berl).62(3), 178–184 (1984).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron57(2), 178–201 (2008).
   PubMed Web of Science ®Google Scholar
• Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Int. Med.257(2), 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res.96(10), 1042–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology63(7), 1187–1192 (2004).
   PubMed Web of Science ®Google Scholar
• Watson GS, Bernhardt T, Reger MA et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer’s disease. Neurobiol. Aging27(1), 38–41 (2006).
   PubMed Web of Science ®Google Scholar
• Nathan DM. Rosiglitazone and cardiotoxicity – weighing the evidence. N. Engl. J. Med.357(1), 64–66 (2007).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med.162(18), 2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet352(9137), 1347–1351 (1998).
   PubMed Web of Science ®Google Scholar
• Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med.163(9), 1069–1075 (2003).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21(5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Di Bari M, Pahor M, Franse LV et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am. J. Epidemiol.153(1), 72–78 (2001).
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol.6(9), 782–792 (2007).
   PubMed Web of Science ®Google Scholar
• Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord.20(6), 338–344 (2005).
   PubMed Web of Science ®Google Scholar